EP0796113A2 - Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes - Google Patents

Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes

Info

Publication number
EP0796113A2
EP0796113A2 EP95942444A EP95942444A EP0796113A2 EP 0796113 A2 EP0796113 A2 EP 0796113A2 EP 95942444 A EP95942444 A EP 95942444A EP 95942444 A EP95942444 A EP 95942444A EP 0796113 A2 EP0796113 A2 EP 0796113A2
Authority
EP
European Patent Office
Prior art keywords
csf
dtpa
protein
rhg
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP95942444A
Other languages
German (de)
English (en)
Inventor
David C. Litzinger
Lloyd D. Ralph
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of EP0796113A2 publication Critical patent/EP0796113A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Definitions

  • the present invention broadly relates to the field of protein modification, and, more specifically, to diethlyenetriaminepentaacetic acid (DTPA) -protein compositions wherein the chelating agent DTPA has been conjugated site-specifically to the N-terminus of the protein, thereby providing a homogenous and well-defined product capable of forming complexes with a variety of metallic radionuclides.
  • the invention relates methods of conjugating DTPA to granulocyte colony stimulating factor (G-CSF) or interleukin-2 (IL-2), thereby providing a useful procedure of radio-labeling such proteins and related proteins including cytokines, while maintaining the structural and functional integrity of the protein.
  • G-CSF granulocyte colony stimulating factor
  • IL-2 interleukin-2
  • Radioactive labeling of proteins and other biological compounds is commonly achieved by iodination.
  • Proteins may be successfully labeled with radioisotopes of iodine by a number of methods; Reogoeczi, E., Iodine- Labeled Plasma Proteins, 1, 53, (CRC Press, Boca Raton, Fla 1982), and antibodies so labeled have been used in radioi munodetection studies in which tumor localization is determined by external imaging; Keenan et al. , J " .
  • Another such method is the "bifunctional chelate" method, in which strong chelating groups are covalently attached to proteins so that the protein bound chelate can then form complexes with a variety of metallic radionuclides; Meares & Goodwin, J. Prot . Chem. , 2, 215-228, (1984), paramagnetic metal ions; Lauffer & Brady, Magn . Reson. Imag. , 3_, 11-16, (1985); Ogan et al. , Invest. Radiol . , 22., 665-671, (1987), and flourescent metals; Mukkala et al., Anal . Bioche . , 12 ., 319-325, (1989) .
  • the reagent most commonly used for the covalent modification of proteins with a chelating agent is the cyclic dianhydride of DTPA.
  • the cyclic dianhydride of DTPA generally forms stronger chelates than the analogs of ethylenetriaminetetraacetic acid (EDTA) ; Perrin et al . , Organic Ligands, IUPAC Chemi cal Data Series No. 22 , (New York, Pergamon Press 1982), and involves less complicated synthesis procedures than those involved when using analogs of EDTA.
  • EDTA ethylenetriaminetetraacetic acid
  • Perrin et al . Organic Ligands, IUPAC Chemi cal Data Series No. 22
  • the cyclic dianhydride of DTPA is stable indefinitely at room temperature, thereby providing for greater control on the conditions of coupling. Hnatowich and McGann, Int . J. Rad.
  • a primary concern for one performing these covalent modifications is that there can be many possible sites on each protein where chelators can be attached.
  • the currently existing methods provide for non-selective attachment at any reactive group, whether located within the protein, such as a lysine side group, or at the N-terminus. This results in a heterogenous population.
  • reaction of DTPA dianhydride with insulin yielded a complex mixture of several products, including cross-linked protein and acylated tyrosine residues; Maisano et al. , Bioconj . Chem. , 3_, 212-217 (1992), while reaction of albumin with DTPA dianhydride produced protein molecules with multiple chelating groups attached; Lauffer _ Brady, Magn . Reson . Imag. , 2, 11-16, (1985) .
  • the number of DTPA groups conjugated to the protein is often given as an average number, as sample preparations are heterogenous, each having protein with both more and less chelating groups than the average number; Hnatowich and McGann, Int. J. Rad. Appl .
  • HSA horse serum albumin
  • chelating agent labeled with 111 In
  • Leung and Meares Biochem. Biophys . Res . Co mun . , 25., 149-155 (1977)
  • the chelate-conjugated HSA at least the population with the most numerous chelating groups and thus representing a large percentage of the followed radioactivity, may have been recognized in vivo as foreign protein; Meares and Goodwin, Jour, of Prot . Chem. , 2, 215-228 (1984) .
  • the advantage of avoiding a random and numerous distribution of products by specifically labeling a single (nonessential) site on a protein is evident.
  • U.S. Patent No. 4,479,930 discloses compositions comprising a dicyclic dianhydride coupled to an amine, and chelated with a radioisotope metallic cation. The compositions are reported to be stable in vivo. Methods of preparing the compositions are also disclosed. It is reported that the initial and final pH of the coupling reaction mixture is pH 7.0 in all instances, and that coupling efficiency (defined as the percentage of anhydride molecules which covalently attach to the polypeptide or protein) is high when anhydride to antibody molar ratios are held at 1:1, but decrease at pH values above or below neutrality. There is no teaching as to the distribution of the DTPA moiety on the proteins or polypeptides of the various reaction products.
  • DTPA:protein conjugates which are advantageous over those previously described due to the fact that the conjugation is site-specific to the N-terminus of the protein, thereby yielding a more well-defined, homogenous composition.
  • the compositions can be produced in large quantities and retain full in vivo bioactivity, either with or without chelated metallic radionuclide.
  • the synthesis described in the present invention is a simple one step reaction wherein a single reactive site is created, providing a useful method for labeling proteins.
  • the DTPA:protein conjugates of the present invention may have potential use in diagnosis, imaging, and/or treatment of leukemia and related diseases.
  • the present invention relates to substantially homogenous preparations of N-terminally chemically modified proteins, and methods therefor.
  • the conjugation of the chelating agent DTPA is site- specific to the N-terminus of the protein, thereby providing a more homogenous and well-defined product as compared to other chelating agent:protein compositions.
  • the present invention relates to a substantially homogenous preparation of DTPA:G-CSF (or analog thereof) and related methods.
  • DTPA chelating agent
  • One working example below demonstrates that the chelating agent DTPA is conjugated site-specifically to the N-terminus of rhG-CSF, and that such compostion is capable of forming complexes with a variety of metallic radionuclides. Since the conjugation is specific to the N-terminus of the G-CSF molecule, the resulting product is a more homgenous and well-defined product than those previously described.
  • the present invention also relates to a method for preparing a labeled protein, said method comprising: (a) reacting a chelating agent with said protein at a pH sufficiently acidic to selectively activate the ⁇ - amino group at the amino terminus of said protein; (b) separating the conjugated protein from non-conjugated protein; (c) adding a metallic cation to said conjugate; and (d) obtaining the labeled protein.
  • This method is described below for rhG-CSF and IL-2, and these provide for additional aspects of the present invention.
  • FIGURE 1 shows the effects of initial pH and DTPA:protein molar ratio on the coupling of rhG-CSF.
  • SDS-PAGE analysis of the following samples was performed: lane 1- MW markers; lanes 2-4, DTPA:rhG-CSF at 5:1, 50:1, and 500:1, respectively, at initial pH 6.0; lanes 5-7, DTPA:rhG-CSF at 5:1, 50:1, and 500:1, respectively, at initial pH 7.0; lanes 8-10, DTPA:rhG- CSF at 5:1, 50:1, and 500:1, respectively, at initial pH 8.0; lane 11, rhG-CSF at pH 6.0; lane 12, rhG-CSF at pH 8.0.
  • FIGURE 2 shows size-exclusion HPLC elution plots for rhG-CSF starting material (line 1), DTPA:rhG- CSF conjugation reaction mixture before passage through a G50 spin column (line 2), and DTPA:rhG-CSF conjugation reaction mixture after passage through a G50 spin column (line 3) . Elution was monitored for absorbance at 280 n .
  • FIGURE 3 shows preparative cation-exchange FPLC elution plots for rhG-CSF starting material (dashed line) and DTPA:rhG-CSF reaction mixture (solid line) . Elution was monitored for absorbance at 280 nm.
  • FIGURE 4 shows analytical cation-exchange HPLC analysis of rhG-CSF (lines 2 and 3) and DTPA:rhG-CSF conjugate (lines 1 and 4) preincubated with lu In. Elution was monitored for absorbance at 220 nm (lines 3 and 4) and for radioactivity (lines 1 and 2, inverted) .
  • FIGURE 5 shows analytical cation-exchange HPLC analysis of rhG-CSF (line 1), DTPA:rhG-CSF conjugate (line 2), and DTPA:rhG-CSF conjugate treated with excess InCl 3 (line 3) . Elution was monitored for absorbance at 220 nm. EDTA (ImM) was added to Buffer A.
  • FIGURE 6 shows silica gel TLC plate analysis of the following samples: lane 1, 0.1 nmol n ⁇ In (indium with a trace of lu In) ; lane 2, 10 nmol ⁇ n In added to 20 nmol DTPA; lane 3, 10 nmol U1 ln incubated with 2 nmol rhG-CSF, followed by addition of 20 nmol DTPA; and lane 4, 10 nmol In incubated with 2 nmol DTPA:rhG-CSF conjugate, followed by addition of 20 nmol DTPA.
  • lanes 2-4 aliquots containing 0.1 nmol ul In were taken from the mixtures and loaded onto the plate.
  • FIGURE 7 shows the MALDI-MS spectrum of the
  • DTPA:rhG-CSF conjugate The spectrum shows the multiply protonated species (1, 2, 3 and 4 protons attached) .
  • FIGURE 8 shows the ion-spray mass spectrum of the DTPA:rhG-CSF conjugate with chelated indium.
  • the conjugate was preincubated with saturating InCl 3 (In:conjugate, 10:1, mol/mol) before analysis.
  • FIGURE 9 shows the ion-spray mass spectrum of rhG-CSF.
  • FIGURE 10 shows peptide mapping of the DTPA:rhG-CSF conjugate.
  • Peptide fragments generated from the DTPA-rhG-CSF conjugate (solid line) and rhG-CSF (dashed line) by proteolysis were reduced, alkylated, and then resolved by reversed-phase HPLC. Elution was monitored for absorbance at 215 nm. The arrow indicates elution of the N-terminal peptide from the digested rhG- CSF sample.
  • FIGURE 11 shows an isoelectric focusing gel (pH 3-10) containing the following samples: lane 1, rhG- CSF; lane 2, DTPA:rhG-CSF conjugate preincubated with excess InCl 3 (In:conjugate, 10:1, mol/mol); lane 3, DTPA:rhG-CSF conjugate; and lane 4, isoelectric point markers.
  • FIGURE 12 shows circular dichroism (CD) spectra of the DTPA:rhG-CSF conjugate without ⁇ ) and with ( ) chelated indium, and of unmodified rhG-CSF
  • FIGURE 13 shows the effects of DTPA conjugation on the in vivo activity of rhG-CSF.
  • Activity WBC count
  • FIGURE 14 shows analytical cation-exchange HPLC analysis of IL-2 (lines 2 and 3) and DTPA:IL-2 conjugate (lines 1 and 4) preincubated with lu In. Elution was monitored for absorbance at 220 nm (lines 3 and 4) and for radioactivity (lines 1 and 2, inverted) .
  • FIGURE 15 shows analytical cation-exchange HPLC analysis of IL-2 (line 1), DTPA:IL-2 conjugate (line 2), and DTPA:IL-2 conjugate treated with excess
  • FIGURE 16 shows silica gel TLC plate analysis of the following samples: lane 1, 0.1 nmol n ⁇ In (indix ⁇ m with a trace of ⁇ In) ; lane 2, 10 nmol n ⁇ In added to 20 nmol DTPA; lane 3, 10 nmol In incubated with 2 nmol IL-2, followed by addition of 20 nmol DTPA; and lane 4, 10 nmol U1 ln incubated with 2 nmol DTPA:IL-2 conjugate, followed by addition of 20 nmol DTPA.
  • lanes 2-4 aliquots containing 0.1 nmol ul In were taken from the mixtures and loaded onto the plate.
  • FIGURE 17 shows peptide mapping of the DTPA:IL-2 conjugate.
  • Peptide fragments generated from the DTPA-IL-2 conjugate (solid line) and IL-2 (dashed line) by proteolysis were reduced, alkylated, and then resolved by reversed-phase HPLC. Elution was monitored for absorbance at 215 nm. The arrow indicates elution of the N-terminal peptide from the digested IL-2 sample.
  • the DTPA:protein conjugates of the present invention are described in more detail in the discussion that follows and are illustrated by the examples provided below.
  • the examples show various aspects of the invention and include results of biological activity testing of various DTPA:protein conjugates.
  • a single reactive site was created such that the resulting DTPA conjugation is site-specific to the N-terminus of the protein, yielding a well-defined and homogeneous composition capable of forming complexes with a variety of metallic radionuclides, while maintaining the structural and functional integrity of the protein.
  • cytokines and related proteins are a variety of cytokines and related proteins.
  • Exemplary proteins contemplated include various hematopoietic factors such as the aforementioned G-CSF, GM-CSF, M-CSF, the interferons (alpha, beta, and gamma), the interleukins (1-14), erythropoietin (EPO) , fibroblast growth factor, stem cell factor (SCF) , megakaryocyte growth and development factor (MGDF) , platelet-derived growth factor (PDGF) , and tumor growth factor (alpha, beta) .
  • G-CSF Granulocyte colony stimulating factor
  • Recombinant human G-CSF (rhG-CSF), expressed in E. coli , contains 175 amino acids, has a molecular weight of 18,798 Da, and is biologically active.
  • Filgrastim a recombinant G-CSF
  • the structure of G-CSF under various conditions has been extensively studied; Lu et al. , J. Biol . Chem. Vol. 231, 8770-8777 (1992), and the three-dimensional structure of rhG-CSF has recently been determined by x-ray crystallography.
  • G-CSF is a member of a class of growth factors sharing a common structural motif of a four ⁇ -helix bundle with two long crossover connections; Hill et al .
  • This family includes GM-CSF, growth hormone, interleukin-2, interleukin-4, and interferon ⁇ .
  • the extent of secondary structure is sensitive to the solvent pH, where the protein acquires an even higher degree of alpha helical content at acidic pH; Lu et al., Arch. Biochem. Biophys . , 286. 81-92 (1989) .
  • G-CSF useful in the practice of this invention may be a form isolated from mammalian organisms or, alternatively, a product of chemical synthetic procedures or of prokaryotic or eukaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by DNA synthesis.
  • Suitable prokaryotic hosts include various bacteria (e.g., E. coli); suitable eukaryotic hosts include yeast (e.g., S. cerevisiae) and mammalian cells (e.g., Chinese hamster ovary cells, monkey cells) .
  • the G-CSF expression product may be glycosylated with mammalian or other eukaryotic carbohydrates, or it may be non-glycosylated.
  • the G-CSF expression product may also include an initial methionine amino acid residue (at position -1) .
  • the present invention contemplates the use of any and all such forms of G-CSF, although recombinant G-CSF, especially E. coli derived, is preferred, for, among other things, greatest commercial practicality.
  • G-CSF analogs have been reported to be biologically functional, and these may also be chemically modified. G-CSF analogs are reported in U.S. Patent No. 4,810,643. Examples of other G-CSF analogs which have been reported to have biological activity are those set forth in AU-A-76380/91, EP 0 459 630, EP 0 272 703, EP 0 473 268 and EP 0 335 423, although no representation is made with regard to the activity of each analog reportedly disclosed. See also AU-A-10948/92, PCT US94/00913 and EP 0 243 153.
  • the G-CSFs and analogs thereof useful in the present invention may be ascertained by practicing the chemical modification procedures as provided herein and testing the resultant product for the desired biological characteristic, such as the biological activity assays provided herein.
  • the desired biological characteristic such as the biological activity assays provided herein.
  • recombinant non-human G-CSF' s such as recombinant murine, bovine, canine, etc. See PCT WO 9105798 and PCT WO 8910932, for example.
  • Interleukin-2 a glycoprotein with a molecular weight of approximately 15,000 daltons, is a member of the group called lymphokines that mediate immune responses in the body. This protein is produced by activated T-cells and is known to possess various activities in vivo . For instance, IL-2 has been reported to enhance thy ocyte mitogenesis, induce T-cell reactivity, regulate gamma interferon, and augment the recovery of the immune function of lymphocytes in selected immunodeficient states. It has potential application in research and the treatment of neoplastic and immunodeficiency diseases and has been employed in therapies for the treatment of cancer.
  • IL-2 useful in the practice of this invention may be a form isolated from mammalian organisms or, alternatively, and especially if an IL-2 analog, a product of chemical synthetic procedures or of prokaryotic or eukaryotic host expression of exogenous DNA sequences obtained by genomic or cDNA cloning or by DNA synthesis.
  • Suitable prokaryotic hosts include various bacteria (e.g., E. coli ) ; suitable eukaryotic hosts include yeast (e.g., S. cerevisiae) and mammalian cells (e.g., Chinese hamster ovary cells, monkey cells) .
  • the IL-2 expression product may be glycosylated with mammalian or other eukaryotic carbohydrates, or it may be non-glycosylated.
  • the IL-2 expression product may also include an initial methionine amino acid residue (at position -1).
  • the present invention contemplates the use of any and all such forms of IL-2 and its analogs, although recombinant IL-2 and analogs, especially E. coli derived, are preferred, for, among other things, greatest commercial practicality.
  • the IL-2 receptor (IL-2R) is constitutively overexpressed in various hematologic malignancies including adult T-cell leukemia (Uchiyama, et al. , 1985), hairy cell leukemia (Trentin, et al . , 1992), chronic lymphocyte leukemia (Rosolen, et al . , 1989),
  • IL-2 diphtheria toxin
  • fusion proteins are specifically cytotoxic to cells that express the high affinity IL-2R (Lorberboum-Galski, et al., 1988b; Williams, et al. , 1990) .
  • a recently described Pseudomonas exotoxin/IL-4 chimeric protein may also prove useful for the treatment of autoimmune diseases, allograft rejections, and many hematologic malignancies where cells express elevated levels of IL-4 receptor (Puri, et al., 1994) .
  • a diphtheria toxin- related human G-CSF fusion protein has also recently been constructed which may have usefulness in the study and treatment of leukemia (Chadwick, et al., 1993) .
  • Conjugation of DTPA to IL-2, IL-4, as well as rhG-CSF may also have potential use in diagnosis, imaging and/or treatment of leukemia and related diseases.
  • Chelatable radiometals for cytotoxic therapy may include 212 Bi, 211 At, and 90 Y. Indeed, antibodies to the IL-2R a chain, and bearing radioisotopes 212 Bi and 90 Y via conjugated bifunctional chelates, are being examined by several investigators (Junghans, et al. , 1993; Parenteau, et al., 1992; Kozak, et al . , 1990) for cytotoxicity towards alloreactive T-cell lines, and for potential radiotherapy.
  • the DTPA useful in the conjugations of the present invention is technical grade DTPA dianhydride.
  • the DTPA:rhG-CSF conjugation occurs at an initial pH of 6.0, and a 50:1 DTPA:rhG-CSF molar ratio.
  • the DTPA:IL-2 conjugation occurs at an initial pH of 6.0, and a 50:1 DTPA:IL-2 molar ratio.
  • the DTPA used for conjugation is initially the dianhydride form, and therefore there exists the potential for undesirable side-reactions such as protein:protein crosslinking; Hnatowich et al.,J " . I- ⁇ mu ⁇ o. Methods , ££, 147-157, (1983b).
  • Reaction conditions such as initial pH and DTPA dianhydride:rhG- CSF molar ratio were therefore investigated in order to minimize the formation of such products.
  • the rhG-CSF was produced using recombinant DNA technology in which E. coli cells were transfected with a DNA sequence encoding human G-CSF as described in U.S. Patent No.
  • the rhG-CSF was prepared as a 2.75- 4 mg/ml solution in 100 mM sodium phosphate buffer, pH 6.0.
  • DTPA dianhydride and tributylphosphine (TBP, technical grade) were obtained from Aldrich (Milwaukee, WI) .
  • rhG-CSF at a concentration of 2.75-4.0 mg/ml in lOOmM sodium phosphate buffer, pH 6.0, pH 7.0, or pH 8.0 was added to the DTPA dianhydride-coated tubes to a final molar ratio of 5:1, 50:1, or 500:1 (DTPA:rhG-CSF) while gently swirling. Aliquots of each sample were maintained and the bulk of the sample passed through a G50 spin column as described; Penefske, H.S., Methods Enzymol . , £__, 527-530, (1979), in order to remove unconjugated DTPA.
  • the reaction mixture with an initial pH of 6.0, and DTPA:rhG-CSF ratio of 50:1 was further analyzed by size-exclusion HPLC.
  • HPLC was performed on a Waters Liquid Chromatograph (Milliford, MA) equipped with a WISP 717 plus auto sampler refrigerated at 5°C, and a 490E multiwavelength UV/Vis detector in line with a Raytest Ramona LS radioisotope detector
  • the pre-G50 spin column sample revealed two major peaks with elution times of 8.65 and 9.53 minutes (Figure 2, line 2).
  • the second major peak coelutes with free DTPA and was nearly eliminated in the post-G50 spin column sample ( Figure 2, line 3) , indicating successful removal of unbound DTPA from the reaction mixture.
  • the elution time of the remaining major peak was unchanged by the G50 spin column and eluted slightly before unreacted rhG-CSF ( Figure 2, line 1) .
  • This peak represents monomeric DTPA-conjugated rhG-CSF.
  • the behavior of the DPTA-conjugated rhG-CSF on this size-exclusion column allows it to be resolved from unmodified rhG-CSF.
  • the ability of the DTPA:rhG-CSF conjugate to chelate ⁇ n In was determined using analytical cation-exchange HPLC and thin layer chromatography.
  • the conjugate was then further analyzed to determine the mass of the conjugate (with and without chelated indium) , the stoichiometic molar ratio of DTPA to rhG-CSF, and the location of the conjugated DTPA moiety on the rhG-CSF.
  • the column was equilibrated in Buffer A (20mM sodium acetate, pH 5.4) and elution was carried out with a 0-40% Buffer B (20mM sodium acetate, 0.5M NaCl, pH 5.4) gradient over 180 minutes at 1.0 ml/minute. Elution was monitored for absorbance at 280 nm and recorded.
  • a reaction mixture (initial pH 6.0, 50:1 DTPA dianhydride: rhG-CSF molar ratio) originally containing 20 mg of rhG-CSF was diluted to 50 ml with Milli-Q water and directly applied to the Hi-Load SP-Sepharose column.
  • a peak representing approximately 13% of the integrated peak areas (Figure 3, peak 2) coeluted with control unreacted rhG-CSF ( Figure 3, dashed line) . This indicates that approximately 13% of the rhG-CSF remained unmodified.
  • a peak eluted between 120 and 130 minutes contained approximately 84% of the total eluted protein (Figure 3, peak 1) .
  • Analytical cation-exchange HPLC was performed with mobile phases of Buffer A (20mM sodium acetate, pH 5.4) , and Buffer B (20mM sodium acetate, 0.5M NaCl, pH 5.4) on a Tosohaas SP-5PW, 7.5 X 7.5 mm column (Montgomery, PA) using the Waters HPLC system.
  • the column was equilibrated with mobile phase A, and separation was performed at 25°C with a 1% B/min linear gradient over 30 minutes at 1.0 ml/minute. Separation was detected by monitoring absorbance at 220 nm, and where applicable, with the radioisotope detector.
  • the chelated conjugate then elutes at a slightly higher salt concentration than the non-chelated conjugate, but still at a salt concentration lower than that of unmodified rhG-CSF.
  • the characteristic retention times of the DTPA:rhG-CSF conjugate with and without chelated metal may be used to monitor metal contamination of the conjugate preparation. Furthermore, this analysis may be used to monitor metal labeling of the conjugate.
  • TLC was performed as previously described (Meares et al., J. Prot . Chem. , 2 215-228, (1984)) with slight modification.
  • An indium stock solution containing InCl 3 with a trace of ⁇ n In was prepared in lOmM HCl, and was used to prepare the following samples: (1) indium added to lOOmM sodium phosphate, pH 6.0; (2) 10 nmol indium added to 20 nmol DTPA in 20mM sodium acetate, pH 5.4; (3) 10 nmol indium incubated with 2 nmol rhG-CSF at room temperature for 10 minutes, followed by addition of 20 nmol DTPA in 20mM sodium acetate, pH 5.4, and (4) 10 nmol indium incubated with 2 nmol DTPA-conjugated rhG-CSF at room temperature for 10 minutes, followed by addition of 20 nmol DTPA in 20mM sodium acetate, pH 5.4.
  • MALDI-MS Matrix-assisted laser desorption/ionization mass specrometry
  • the mass of the DTPA:rhG-CSF conjugate was determined by MALDI-MS ( Figure 7) .
  • the acquired spectrum revealed multiply charged ions in addition to the monoprotonated species.
  • the mass obtained by averaging the peak series was 19,171.7 ( ⁇ 7.3) Da.
  • the calculated MW for a single DTPA conjugated to rhG-CSF is 19,170.8 Da. Therefore, in general agreement with the TLC analysis, the observed mass indicated a DTPA to rhG-CSF molar ratio of 1:1 for the DTPA:rhG-CSF conjugate.
  • Ion-spray mass spectrometry was performed with a Perkin-Elmer Sciex API III mass spectrometer (Norwalk, CT) equipped with an ion-spray interface by method of flow injection. Samples were diluted in - 23 -
  • the measured mass of the conjugate with chelated indium was 19,286 ( ⁇ 1.7) Da, which is in agreement with the calculated mass of 19,285.6 Da.
  • the measured mass was 18,798 ( ⁇ 1.8) Da ( Figure 9), in agreement with the calculated mass of 18,798.5 Da.
  • rhG-CSF or DTPA:rhG-CSF was dried in a speed vacuum, reconstituted in 100 ⁇ l of 8M Urea and sonicated for 10 minutes. After sonication, 10 ⁇ l of 1M Tris-HCl, pH 8.5 and 2.5 ⁇ g of EndoLys-C (Wako Chemicals, Richmond, VA) from a 1 mg/ml stock solution in lOmM Tris HCl, pH 8.5, was added. The total volume was adjusted to 200 ⁇ l with distilled water, and the proteolytic digestion was carried out for 7 hours at room temperature.
  • Peptide analysis was performed using a Waters HPLC system consisting of two 510 pumps, a WISP 712 autoinjector, and a 481LC spectrophotometer all controlled through a system interface module by the system software, Maxima.
  • the generated peptides were eluted with a linear gradient of 3-76% Solvent B (0.1% TFA, 95% acetonitrile) over 115 minutes. Elution was monitored for absorbance at 215 nm.
  • Individual peptides from the rhG-CSF standard peptide map were collected and identified by amino acid composition analysis and N- terminal sequencing as described; Souza et al. , Science, 222., 61-65, (1986) .
  • DTPA:rhG-CSF were prepared and analyzed as described above.
  • a peak eluting from the unmodified rhG-CSF sample at 60 minutes was absent from the DTPA:rhG-CSF conjugate sample ( Figure 10) .
  • the material eluting in this peak was determined by amino acid composition analysis and N-terminal sequencing to be the N-terminal 17 residues of rhG-CSF.
  • the corresponding N- terminal peptide fragment from the DTPA:rhG-CSF conjugate was modified, yielding a new partially split double peak eluting at 62 minutes.
  • Analysis of peptide from each of these partially separated peaks by mass spectrometry revealed the first peak to have the expected mass of the N-terminal peptide with conjugated DTPA, while the mass of the second peak material suggested conjugated peptide contaminated with iron.
  • N-terminal peptide contains the N-terminus, one threonine, three serine residues and a lysine residue. Cleavage of the peptide by EndoLys-C indicates that the lysine is unmodified. Acylation of threonine or serine residues is highly unlikely at pH 6.0. Undigested DTPA:rhG-CSF conjugate subjected to N-terminal sequencing revealed >99% blocked N-terminus, indicating the single DTPA moiety on the protein is conjugated to the N-terminus.
  • Isoelectric focusing was performed using Novex pH 3-10 gels (San Diego, CA) with a pi 3.5 - 8.5 performance range. Samples were diluted 1:1 with sample buffer, and 5 ⁇ g of protein was loaded into each lane. The gels were run at constant voltages of 100 V for 1 hour, 200 V for 2 hours, and then 500 V for 0.5 hour. All fixing, staining and destaining procedures were done to the manufacturer's specifications.
  • the DTPA:rhG-CSF conjugate revealed a single major band of pi 4.9 following isoelectric focusing ( Figure 11, lane 3) .
  • Preincubation of the conjugate with excess InCl 3 (In:conjugate, 10:1, mol/mol) shifted the band to pi 5.3 ( Figure 11, lane 2).
  • the pi values of the conjugate, both.with and without indium, were lower than that of rhG-CSF, pi 6.0 ( Figure 11, lane 1) .
  • the conjugation of DTPA, concomitant with the loss of the N-terminal free amino group substantially decreased the pi of the rhG-CSF.
  • chelated indium slightly increased the pi of the conjugate.
  • the characteristic isoelectric points of the DTPA:rhG-CSF conjugate with and without chelated metal may also be used to monitor metal contamination and metal labeling of the conjugate preparation.
  • the DTPA conjugation is specific to the N-terminus of the rhG-CSF; and (4) the conjugation of DTPA to rhG-CSF decreases the pi of rhG-CSF.
  • Circular Dichroism analysis was used to study the effects on rhG-CSF secondary structure resulting from conjugation of a chelating group to the N-terminus of rhG-CSF.
  • Circular Dichroism (CD) spectra were obtained with a Jasco J-720 spectropolarimeter (Japan Spectroscopic Co., LTD., Tokyo, Japan). Samples (0.078 mg/ml protein) were analyzed at 10°C in 20mM sodium acetate, pH 5.4.
  • the CD spectra of the DTPA:rhG-CSF conjugate overlays that of unmodified rhG-CSF ( Figure 12), each revealing ellipticity minima at 208nm and 222nm.
  • the conjugation reaction described above was carried out on the related growth factor, interleukin-2 (IL-2) .
  • IL-2 interleukin-2
  • the ability of the DTPA:IL-2 conjugate to chelate lu In was evaluated using cation-exchange HPLC as described above.
  • the stoichiometric molar ratio of DTPA:IL-2 was determined as well as the distribution of the DTPA moiety on the IL-2.
  • the IL-2 was produced using recombinant DNA technology in which E. coli cells were transfected with a DNA sequence encoding IL-2 as described in European patent 0136489 (Souza et al. ) .
  • the IL-2 was prepared as a 1.82 mg/ml solution in 100 mM sodium phosphate buffer, pH 6.0.
  • DTPA dianhydride and tributylphosphine (TBP, technical grade) were obtained from Aldrich (Milwaukee, WI) .
  • the conjugates were prepared as described in Example 2 above. Analysis of the DTPA:IL-2 Conjugate
  • TLC Thin Layer Chromatography
  • TLC was performed as described above in order to determine the ability of the DTPA:IL-2 conjugate to chelate 111 In, and to determine the stoichiometric molar ratio of DTPA to IL-2.
  • chelation of U1 ln by DTPA results in migration of all radioactivity from near the solvent front ( Figure 16, compare lanes 1 and 2).
  • Line graphs of the individual lanes were generated and integration of the peak areas from lane 4 revealed 18% of the radioactivity remained at the origin.
  • DTPA:IL-2 conjugate in order to determine the location of the conjugated DTPA moiety on the IL-2.
  • Peptide fragments were prepared as described above.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions de protéines/d'acide diéthylènetriamine pentacétique (DTPA) dans lesquelles l'agent chélateur DTPA a été conjugué de manière dirigée à l'extrémité azotée de la protéine, permettant ainsi la formation d'un produit homogène et bien défini, capable de former des complexes avec une diversité de radionucléides métalliques. Les compositions selon cette invention peuvent être produites en grande quantité et conserver une bioactivité in vivo totale, avec ou sans les radionucléides métalliques chélatés. Elles peuvent convenir au diagnostic, à l'imagerie et/ou au traitement de la leucémie et des maladies associées.
EP95942444A 1994-11-17 1995-11-17 Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes Withdrawn EP0796113A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34248194A 1994-11-17 1994-11-17
US342481 1994-11-17
PCT/US1995/015072 WO1996015816A2 (fr) 1994-11-17 1995-11-17 Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes

Publications (1)

Publication Number Publication Date
EP0796113A2 true EP0796113A2 (fr) 1997-09-24

Family

ID=23342010

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95942444A Withdrawn EP0796113A2 (fr) 1994-11-17 1995-11-17 Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes

Country Status (5)

Country Link
EP (1) EP0796113A2 (fr)
JP (1) JPH10509179A (fr)
AU (1) AU709012B2 (fr)
MX (1) MX9703549A (fr)
WO (1) WO1996015816A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US6017876A (en) * 1997-08-15 2000-01-25 Amgen Inc. Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
CA2359573C (fr) 1999-01-19 2010-04-20 Biostream, Inc. Conjugues de facteurs stimulant les colonies cellulaires pour cibler et visualiser des infections et des inflammations
IT201900011013A1 (it) 2019-07-05 2021-01-05 Sapienza Univ Di Roma Composto e composizione radiofarmaceutici per l’imaging con tecnica di Tomografia a Emissione di Positroni (PET) di cellule positive al recettore dell’interleuchina-2, processo per la loro preparazione, relativo kit e loro usi.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ234173A (en) * 1989-06-23 1993-10-26 Cancer Res Campaign Tech Alpha-melanocyte stimulating hormone derivative (alphamsh)-targetted moiety conjugate

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9615816A2 *

Also Published As

Publication number Publication date
WO1996015816A2 (fr) 1996-05-30
AU709012B2 (en) 1999-08-19
WO1996015816A3 (fr) 1996-08-08
MX9703549A (es) 1998-02-28
JPH10509179A (ja) 1998-09-08
AU4366796A (en) 1996-06-17

Similar Documents

Publication Publication Date Title
US5225180A (en) Technetium-99m labeled somatostatin-derived peptides for imaging
FI81263C (fi) Foerfarande foer maerkning av en maolsoekande biologiskt aktiv molekyl och metalltionein.
KR100235137B1 (ko) 모노아민, 다아민, 티올-함유 금속 킬레이트제
EP0614379B1 (fr) Peptides marqués au technetium-99m utiles en imagerie
US5277892A (en) In vivo lymphocyte tagging
JP7327762B2 (ja) 修飾抗体、および、放射性金属標識抗体
EP0721353A1 (fr) Structures polypeptidiques qui peuvent fixer des metaux et que l'on peut cibler
US5728369A (en) Radioactive phosphorus labeling of proteins for targeted radiotherapy
KR100385340B1 (ko) 금속킬레이트형성펩티드및그의용도
AU709012B2 (en) Stable N-terminally linked DTPA:protein compositions and methods
MXPA97003549A (en) Stable dietilentriaminopentaacetic acid, jointed by the end of n: compositions of protein and met
US6551574B2 (en) Tuftsin metallopeptide analogs and uses thereof
CA2205064A1 (fr) Compositions stables de proteines/acide diethylenetriamine pentacetique a liaison n-terminale et procedes associes
WO1993009816A1 (fr) Procede de diagnostic et de traitement du cancer
Ralph et al. Site-specific conjugation of diethylenetriaminepentaacetic acid to recombinant human granulocyte-colony-stimulating factor: preservation of protein structure and function
EP0700930B1 (fr) Peptides à affinité pour des tumeurs et composés radioactifs diagnostiques et thérapeutiques les contenant
US5643549A (en) Leukostimulatory agent for in vivo leukocyte tagging
EP0493526A1 (fr) Compositions de radionuclides therapeutiques stables et leurs procedes de preparation
US20220288245A1 (en) Radiopharmaceutical compound and composition for positron emission tomography (pet) imaging of interleukin-2 receptor positive cells, process for the preparation thereof, related kit and uses thereof
Litzinger et al. A method for preparing chelate-cytokine conjugates with retention of protein structure, biological activity, and pharmacokinetic properties
Liu et al. 99m Tc complex conjugated to insulin: CNS radio-pharmaceuticals design based on principles of blood-brain barrier transport vector
CA2225326A1 (fr) Methode simple et efficace pour preparer des peptides marques au technetium 99m
JPH08231587A (ja) 金属キレート形成性ペプチド、その用途及びその製造方法
JPH0853494A (ja) 腫瘍親和性ペプチド、該ペプチドを含有してなる放射性診断剤および放射性治療剤

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19970509

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 970509;LV PAYMENT 970509;SI PAYMENT 970509

17Q First examination report despatched

Effective date: 19991230

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMGEN INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: AMGEN INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030603